506

MOLECULAR PARTNERS DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Molecular Partners AG and Encourages Investors to Contact the Firm

Retrieved on: 
Sunday, September 11, 2022
Class Action Lawsuit, Professional Services, Legal, District court, NASDAQ, ADSS, U.S. Securities and Exchange Commission, Class, AMG, Register, ADS, Molecule, FDA, IPO, P.C, EUA, Defendant, Cancer, Special-purpose acquisition company, Registration statement, COVID, 506, SEC, Court, News, Company, Person, Form, Molecular Partners, Telephone, Lists of schools in England, COVID-19, Food, Prospectus, Jeanne Eagels, Novartis, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Security (finance), Pharmaceutical industry, Amgen

Investors have until September 12, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until September 12, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Molecular Partners operates as a clinical-stage biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutic proteins.
  • Among other product candidates, Molecular Partners is developing ensovibep as a treatment for COVID-19 in collaboration with Novartis AG (Novartis).
  • In addition, Molecular Partners is developing MP0310 (AMG 506) for the treatment of certain types of cancer in collaboration with Amgen Inc. (Amgen).

MOLN MONDAY DEADLINE: ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Molecular Partners AG Investors to Secure Counsel Before Important September 12 Deadline in Securities Class Action – MOLN

Retrieved on: 
Saturday, September 10, 2022
Titan, NASDAQ, Class, AMG, Amgen, IPO, EUA, Facebook, Cancer, Advertising, 506, Court, LinkedIn, GLOBE, Molecular Partners, I-Space (Chinese company), Lists of schools in England, COVID-19, Food, TO, WHY, Twitter, THE, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Insurance, Tobacco

WHAT TO DO NEXT: To join the Molecular Partners class action, go to https://rosenlegal.com/submit-form/?case_id=7548 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Molecular Partners class action, go to https://rosenlegal.com/submit-form/?case_id=7548 or call Phillip Kim, Esq.
  • If you wish to serve as lead plaintiff, you must move the Court no later than September 12, 2022.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

MOLECULAR PARTNERS AG (NASDAQ: MOLN) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Molecular Partners AG (NASDAQ: MOLN)

Retrieved on: 
Tuesday, September 6, 2022
COVID-19, ADS, EUA, Prospectus, Cancer, Securities Act of 1933, Securities Exchange Act of 1934, District court, Register, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Class, 506, Novartis, IPO, Food, Advertising, Defendant, SEC, Court, Investment, NEW, Special-purpose acquisition company, AMG, Company, Partner, GLOBE, FDA, Labour government, News, Form, Molecular Partners, The Legal 500, Lists of action films, American, COVID, Trial of the century, Registration statement, Tobacco, Security (finance), Pharmaceutical industry, Renewable energy, Molecule, Amgen

NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or otherwise acquired: (a) Molecular Partners AG (“Molecular Partners” or the “Company”) American Depositary Shares (“ADSs”) pursuant and/or traceable to the Offering Documents issued in connection with the Company’s initial public offering conducted on or about June 16, 2021 (the “IPO”); and/or (b) Molecular Partners securities between June 16, 2021 and April 26, 2022, both dates inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Southern District of New York and alleges violations of the Securities Act of 1933 and Securities Exchange Act of 1934.

Key Points: 
  • If so, please visit Molecular Partners AG Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • Molecular Partners operates as a clinical-stage biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutic proteins.
  • Among other product candidates, Molecular Partners is developing ensovibep as a treatment for COVID-19 in collaboration with Novartis AG (Novartis).
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Molecular Partners AG of Class Action Lawsuit and Upcoming Deadline – MOLN

Retrieved on: 
Tuesday, September 6, 2022
Ext, COVID-19, EUA, Lists of action films, ADS, Prospectus, Cancer, Securities Exchange Act of 1934, American depositary receipt, Securities Act of 1933, District court, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Register, NASDAQ, Lists of schools in England, Person, Class, 506, Novartis, IPO, Food, Defendant, SEC, Court, U.S. Securities and Exchange Commission, Complaint, Special-purpose acquisition company, AMG, Molecule, Company, GLOBE, FDA, News, Form, Molecular Partners, Pomerantz, ADSS, COVID, Registration statement, Security (finance), Pharmaceutical industry, Amgen

NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Molecular Partners AG (Molecular Partners or the Company) (NASDAQ: MOLN) and certain of its officers and directors.

Key Points: 
  • NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Molecular Partners AG (Molecular Partners or the Company) (NASDAQ: MOLN) and certain of its officers and directors.
  • Molecular Partners operates as a clinical-stage biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutic proteins.
  • Among other product candidates, Molecular Partners is developing ensovibep as a treatment for COVID-19 in collaboration with Novartis AG (Novartis).
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

ROSEN, A TOP RANKED LAW FIRM, Encourages Molecular Partners AG Investors to Secure Counsel Before Important Deadline in Securities Class Action – MOLN

Retrieved on: 
Sunday, September 4, 2022
Titan, TO, COVID-19, EUA, Cancer, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NASDAQ, WHY, Lists of schools in England, Class, 506, IPO, Food, LinkedIn, Court, AMG, GLOBE, Amgen, Molecular Partners, Twitter, THE, Facebook, Advertising, I-Space (Chinese company), Insurance, Tobacco

WHAT TO DO NEXT: To join the Molecular Partners class action, go to https://rosenlegal.com/submit-form/?case_id=7548 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Molecular Partners class action, go to https://rosenlegal.com/submit-form/?case_id=7548 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Molecular Partners AG of Class Action Lawsuit and Upcoming Deadline – MOLN

Retrieved on: 
Tuesday, August 30, 2022
Ext, COVID-19, EUA, Lists of action films, ADS, Prospectus, Cancer, Securities Exchange Act of 1934, American depositary receipt, Securities Act of 1933, District court, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Register, NASDAQ, Lists of schools in England, Person, Class, 506, Novartis, IPO, Food, Defendant, SEC, Court, U.S. Securities and Exchange Commission, Complaint, Special-purpose acquisition company, AMG, Molecule, Company, GLOBE, FDA, News, Form, Molecular Partners, Pomerantz, ADSS, COVID, Registration statement, Security (finance), Pharmaceutical industry, Amgen

NEW YORK, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Molecular Partners AG (Molecular Partners or the Company) (NASDAQ: MOLN) and certain of its officers and directors.

Key Points: 
  • NEW YORK, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Molecular Partners AG (Molecular Partners or the Company) (NASDAQ: MOLN) and certain of its officers and directors.
  • Molecular Partners operates as a clinical-stage biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutic proteins.
  • Among other product candidates, Molecular Partners is developing ensovibep as a treatment for COVID-19 in collaboration with Novartis AG (Novartis).
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

MOLECULAR PARTNERS AG (NASDAQ: MOLN) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Molecular Partners AG (NASDAQ: MOLN)

Retrieved on: 
Tuesday, August 30, 2022
COVID-19, ADS, EUA, Prospectus, Cancer, Securities Act of 1933, Securities Exchange Act of 1934, District court, Register, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Class, 506, Novartis, IPO, Food, Advertising, Defendant, SEC, Court, Investment, NEW, Special-purpose acquisition company, AMG, Company, Partner, GLOBE, FDA, Labour government, News, Form, Molecular Partners, The Legal 500, Lists of action films, American, COVID, Trial of the century, Registration statement, Tobacco, Security (finance), Pharmaceutical industry, Renewable energy, Molecule, Amgen

NEW YORK, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or otherwise acquired: (a) Molecular Partners AG (“Molecular Partners” or the “Company”) American Depositary Shares (“ADSs”) pursuant and/or traceable to the Offering Documents issued in connection with the Company’s initial public offering conducted on or about June 16, 2021 (the “IPO”); and/or (b) Molecular Partners securities between June 16, 2021 and April 26, 2022, both dates inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Southern District of New York and alleges violations of the Securities Act of 1933 and Securities Exchange Act of 1934.

Key Points: 
  • If so, please visit Molecular Partners AG Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • Molecular Partners operates as a clinical-stage biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutic proteins.
  • Among other product candidates, Molecular Partners is developing ensovibep as a treatment for COVID-19 in collaboration with Novartis AG (Novartis).
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

MOLN NOTICE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Molecular Partners AG Investors to Secure Counsel Before Important Deadline in Securities Class Action – MOLN

Retrieved on: 
Saturday, August 27, 2022
Titan, TO, COVID-19, EUA, Cancer, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NASDAQ, WHY, Lists of schools in England, Class, 506, IPO, Food, LinkedIn, Court, AMG, GLOBE, Amgen, Molecular Partners, Twitter, THE, Facebook, Advertising, I-Space (Chinese company), Insurance, Tobacco

WHAT TO DO NEXT: To join the Molecular Partners class action, go to https://rosenlegal.com/submit-form/?case_id=7548 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Molecular Partners class action, go to https://rosenlegal.com/submit-form/?case_id=7548 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Molecular Partners AG of Class Action Lawsuit and Upcoming Deadline – MOLN

Retrieved on: 
Wednesday, August 24, 2022
Ext, COVID-19, EUA, Lists of action films, ADS, Prospectus, Cancer, Securities Exchange Act of 1934, American depositary receipt, Securities Act of 1933, District court, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Register, NASDAQ, Lists of schools in England, Person, Class, 506, Novartis, IPO, Food, Defendant, SEC, Court, U.S. Securities and Exchange Commission, Complaint, Special-purpose acquisition company, AMG, Molecule, Company, GLOBE, FDA, News, Form, Molecular Partners, Pomerantz, ADSS, COVID, Registration statement, Security (finance), Pharmaceutical industry, Amgen

NEW YORK, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Molecular Partners AG (Molecular Partners or the Company) (NASDAQ: MOLN) and certain of its officers and directors.

Key Points: 
  • NEW YORK, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Molecular Partners AG (Molecular Partners or the Company) (NASDAQ: MOLN) and certain of its officers and directors.
  • Molecular Partners operates as a clinical-stage biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutic proteins.
  • Among other product candidates, Molecular Partners is developing ensovibep as a treatment for COVID-19 in collaboration with Novartis AG (Novartis).
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

MOLECULAR PARTNERS AG (NASDAQ: MOLN) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Molecular Partners AG (NASDAQ: MOLN)

Retrieved on: 
Monday, August 22, 2022
COVID-19, ADS, EUA, Prospectus, Cancer, Securities Act of 1933, Securities Exchange Act of 1934, District court, Register, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Class, 506, Novartis, IPO, Food, Advertising, Defendant, SEC, Court, Investment, NEW, Special-purpose acquisition company, AMG, Company, Partner, GLOBE, FDA, Labour government, News, Form, Molecular Partners, The Legal 500, Lists of action films, American, COVID, Trial of the century, Registration statement, Tobacco, Security (finance), Pharmaceutical industry, Renewable energy, Molecule, Amgen

NEW YORK, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or otherwise acquired: (a) Molecular Partners AG (“Molecular Partners” or the “Company”) American Depositary Shares (“ADSs”) pursuant and/or traceable to the Offering Documents issued in connection with the Company’s initial public offering conducted on or about June 16, 2021 (the “IPO”); and/or (b) Molecular Partners securities between June 16, 2021 and April 26, 2022, both dates inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Southern District of New York and alleges violations of the Securities Act of 1933 and Securities Exchange Act of 1934.

Key Points: 
  • If so, please visit Molecular Partners AG Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • Molecular Partners operates as a clinical-stage biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutic proteins.
  • Among other product candidates, Molecular Partners is developing ensovibep as a treatment for COVID-19 in collaboration with Novartis AG (Novartis).
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.